|
1000
|
Abstract/Summary
|
-
<jats:sec><jats:title>Purpose</jats:title><jats:p> No large-scale prospective randomized study with a long-term follow-up period has evaluated the survival outcomes of preconcurrent chemoradiotherapy (CCRT) 18-fluorodeoxyglucose positron emission tomography–computed tomography (<jats:sup>18</jats:sup>FDG PET–CT) in patients with non–human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> We included patients with stage I–IVA p16-negative OPSCC receiving definitive CCRT and categorized them into two groups according to pre-CCRT <jats:sup>18</jats:sup>FDG PET–CT and compared their outcomes: the case group consisted of patients who underwent pre-CCRT <jats:sup>18</jats:sup>FDG PET–CT, whereas the comparison group consisted of patients who did not receive pre-CCRT <jats:sup>18</jats:sup>FDG PET–CT. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> The final cohort consisted of 3942 patients (1663 and 2279 in the case and comparison groups, respectively). According to multivariable Cox regression analysis, pre-CCRT <jats:sup>18</jats:sup>FDG PET–CT was not a significant prognostic factor for overall survival in patients with stages I–II of p16-negative OPSCC receiving standard CCRT. The adjusted hazard ratio (95% confidence interval) of all-cause death for the patients with advanced stages (III–IVA) of p16-negative OPSCC receiving pre-CCRT <jats:sup>18</jats:sup>FDG PET–CT was 0.75 (0.87–0.94, P = 0.0236). </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Routine use of pre-CCRT <jats:sup>18</jats:sup>FDG PET–CT is not necessary for each patient with p16-negative OPSCC. Pre-CCRT <jats:sup>18</jats:sup>FDG PET–CT is associated with improved survival in patients with stage III–IVA p16-negative OSCC, but might be not in those with stage I–II p16-negative OPSCC. </jats:p></jats:sec><jats:sec><jats:title>Condensed abstract</jats:title><jats:p> No large-scale prospective randomized study with a long-term follow-up period has evaluated the survival outcomes of preconcurrent chemoradiotherapy (CCRT) 18-fluorodeoxyglucose positron emission tomography–computed tomography (<jats:sup>18</jats:sup>FDG PET–CT) in patients with p16-negative oropharyngeal squamous cell carcinoma (OPSCC). Our study is the first, largest, homogenous modality study on PET–CT including a long-term follow-up cohort to examine the survival outcomes of pre-CCRT <jats:sup>18</jats:sup>FDG PET–CT or non-pre-CCRT PET–CT for patients with p16-negative OPSCC receiving standard CCRT stratified by different clinical stages. Routine use of pre-CCRT <jats:sup>18</jats:sup>FDG PET–CT is not necessary for each patient with p16-negative OPSCC. Pre-CCRT <jats:sup>18</jats:sup>FDG PET–CT is associated with improved survival in patients with stage III–IVA p16-negative OPSCC, but might be not in those with stage I–II p16-negative OPSCC. </jats:p></jats:sec>
|
|
1000
|
Hinweis
|
-
DeepGreen-ID: 934690a25fc74a9887019f594920a63c ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
|
